Key result
This editorial highlights that treatment delays for acute coronary syndromes significantly impact patient outcomes and emphasizes the need to modify health care systems to reduce symptom-to-treatment time.
Answers are grounded in this paper and cite their sources.
Reducing treatment delays for ACS patients requires modifying health care systems rather than relying solely on public education to change patient behavior.
See also pp. 204–11 and 218–23 As clinicians, we are sometimes surprised by the patient who stoically waits days with a serious illness before presenting to the ED, or irritated by the one who anxiously rushes in within minutes of developing a trivial complaint. For the most part, the timing of such ED presentations has limited impact on patient outcomes. In the case of acute coronary syndromes (ACS), however, patients’ decisions about when to seek care can determine who lives and who dies.1 Two papers in this issue examine delays from symptom onset to ED presentation among patients with suspected ACS.2,3 In the first study, Taylor et al. surveyed 150 ED chest pain patients about the timing of their symptoms and their decision to come to the ED. He defined ‘delayed presentation’ as being >3 h from symptom onset to ED arrival, and found that over half were delayed based on this definition.2 Ingarfield et al.'s paper looked at a sicker patient population, those admitted from the ED with a diagnosis of either acute myocardial infarction (AMI) or angina. Here delayed presentation was defined as >30 min from symptom onset to deciding to seek care, and they found that 74% were delayed.3 The first question to ask is whether delays of as little as 30 min matter for ACS patients. The short answer is yes. The benefit of thrombolysis in AMI almost doubles from 37 lives saved/1000 patients treated when given in the second hour after symptom onset to 65 lives saved/1000 patients treated when given in the first hour,1 and the UK National Health Service estimates that ‘every half hour's delay is equivalent to a year of life lost’.4 Other findings from both studies confirm what others have shown, namely that presentation delay is a major component of delayed reperfusion.5 In Taylor's study the median delay from symptom onset to decision to seek medical care was 2 h, compared with 52 min median time for transport to hospital after deciding to seek care, and the 35–40 min median door-to-needle time delays that are typical in many jurisdictions.6 Both Taylor and Ingarfield suggest that public education campaigns may be helpful to reduce the interval between symptom onset and the decision to seek care. However, expensive and sophisticated public education campaigns have failed to have any substantial impact on reducing this interval,7 and may have unintended effects, like increasing the number of non-cardiac chest pain patients presenting to EDs.8 Indeed Taylor found that almost 97% of the patients knew that people with chest pain should go to an ED, and 83.3% thought it was important or extremely important to do so. Yet between 25% and 44% of patients still tried to contact their GP before going to the hospital. This suggests that the public may know what to do, but not be routinely prepared to do it. Ultimately, what is important is the total symptom-to-treatment time, and reducing delays at any point along the interval will likely be of benefit. To date we have not been very successful at modifying patient behaviour, so a more effective strategy might be to focus on modifying the health care systems. For example, about half of the patients in Ingarfield's study called an ambulance; for them, reducing the time taken to get them to hospital, ensuring that they can be given proven treatments like acetylsalicylic acid (ASA) before arrival,9 and consideration of interventions like prehospital 12-lead electrocardiograms (ECG) or thrombolysis could all reduce delays and/or improve outcomes.5 For other patients, we need to ensure that GPs (and their receptionists) routinely advise chest pain patients to immediately go to an ED. Once in the ED, chest pain protocols (including the rapid acquisition of a first ECG), and empowering emergency physicians to administer thrombolytics or initiate transfer to a cardiac catheterization lab without the need to first involve a cardiologist may reduce treatment delays.6,10 To achieve this, we first have to rethink some of our own ideas about ‘delays’ and how to measure them. Taylor defined ‘delayed presentation’ as >3 h total prehospital time. However, there is good evidence that delays of less than 3 h are associated with increased mortality, and reduced efficacy of i.v. thrombolytics;11,12 Similarly, studies of hospital performance have sometimes adopted median door-to-needle or call-to-needle time as performance benchmark;6,13 the result is that a hospital can be considered a ‘good’ performer if their median performance equals the benchmark.6 However, that means that half of all patients are treated outside of the recommended time. A better way to judge performance is to look at the absolute number of patients treated within the target time frame.14 Patients and physicians are united by at least one goal: to see improved outcomes. Achieving this will require careful attention to delays at the patient and health system levels, but for the foreseeable future system performance may be more easily modified. This will occur more quickly if we begin now to routinely measure and compare our own performance, then respond to the data by taking the steps necessary to speed care for cardiac patients. None declared.
No takes yet. Share an insight, caveat, or question.
Michael J. Schull (2005) conducted an editorial in Acute coronary syndromes (ACS). This editorial highlights that treatment delays for acute coronary syndromes significantly impact patient outcomes and emphasizes the need to modify health care systems to reduce symptom-to-treatment time.
Synapse has enriched 10 related papers. Consider them for comparative context: